Home > Newsletters > Washington Drug Letter > Draft Guidance Suggests Updated Assessment of Suicidal Events in Trials
Washington Drug Letter
Aug. 20, 2012 | Vol. 44 No. 33
Draft Guidance Suggests Updated Assessment of Suicidal Events in Trials
Drugmakers should use an updated instrument for the prospective assessment of suicidal thoughts and behaviors during clinical trials and follow new FDA advice on which trials and patients need such assessments, according to a new draft guidance.
ePublishing :: CMS, Hosting & Web Development | © Copyright by FDAnewsAll rights reserved. Do not duplicate or redistribute in any form.